Firefly Neuroscience (NASDAQ:AIFF) Major Shareholder Windsor Private Capital Lp Sells 33,500 Shares

Firefly Neuroscience, Inc. (NASDAQ:AIFF) major shareholder Windsor Private Capital Lp sold 33,500 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $2.46, for a total value of $82,410.00. Following the transaction, the insider owned 1,334,026 shares of the company’s stock, valued at $3,281,703.96. This trade represents a 2.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Windsor Private Capital Lp also recently made the following trade(s):

• On Wednesday, October 22nd, Windsor Private Capital Lp sold 78,031 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.07, for a total value of $161,524.17.
• On Tuesday, October 21st, Windsor Private Capital Lp sold 19,222 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.40, for a total value of $46,132.80.
• On Friday, October 17th, Windsor Private Capital Lp sold 45,036 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.55, for a total value of $114,841.80.
• On Thursday, October 16th, Windsor Private Capital Lp sold 40,139 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.65, for a total value of $106,368.35.
• On Wednesday, October 15th, Windsor Private Capital Lp sold 17,500 shares of Firefly Neuroscience stock. The stock was sold at an average price of $2.74, for a total value of $47,950.00.
• On Tuesday, October 14th, Windsor Private Capital Lp sold 29,500 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.74, for a total value of $80,830.00.
• On Monday, October 13th, Windsor Private Capital Lp sold 32,136 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.65, for a total value of $85,160.40.
• On Friday, October 10th, Windsor Private Capital Lp sold 74,810 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.70, for a total value of $201,987.00.
• On Thursday, October 9th, Windsor Private Capital Lp sold 30,126 shares of Firefly Neuroscience stock. The shares were sold at an average price of $2.94, for a total value of $88,570.44.

Firefly Neuroscience Price Performance

AIFF stock opened at $2.03 on Thursday. The business has a fifty day moving average price of $2.75 and a 200 day moving average price of $2.95. Firefly Neuroscience, Inc. has a fifty-two week low of $1.86 and a fifty-two week high of $17.20. The stock has a market capitalization of $27.30 million, a price-to-earnings ratio of -0.81 and a beta of 2.11.

Firefly Neuroscience (NASDAQ:AIFF) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter. Firefly Neuroscience had a negative net margin of 5,335.75% and a negative return on equity of 464.02%.

Institutional Investors Weigh In On Firefly Neuroscience

A hedge fund recently raised its stake in Firefly Neuroscience stock. Geode Capital Management LLC grew its position in Firefly Neuroscience, Inc. (NASDAQ:AIFF) by 92.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 120,604 shares of the company’s stock after buying an additional 58,067 shares during the period. Geode Capital Management LLC owned 0.94% of Firefly Neuroscience worth $341,000 at the end of the most recent reporting period. Institutional investors own 4.96% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Firefly Neuroscience in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About Firefly Neuroscience

Firefly Neuroscience, Inc, a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.